TECARFARIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H14F6O5
Molecular Weight	460.3233
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(OC(=O)C1=CC=C(CC2=C(O)C3=CC=CC=C3OC2=O)C=C1)(C(F)(F)F)C(F)(F)F

InChI

InChIKey=QFLNTQDOVCLQKW-UHFFFAOYSA-N

InChI=1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3

HIDE SMILES / InChI

Molecular Formula	C21H14F6O5
Molecular Weight	460.3233
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.globenewswire.com/news-release/2019/03/11/1751182/0/en/Espero-BioPharma-Announces-Tecarfarin-Receives-FDA-Orphan-Drug-Designation-for-Patients-with-End-Stage-Renal-Disease-and-Atrial-Fibrillation.html | https://clinicaltrials.gov/ct2/show/NCT02522221 | https://www.ncbi.nlm.nih.gov/pubmed/20622200

Tecarfarin (also known as ATI-5923), an anticoagulant, is a vitamin K reductase antagonist. Tecarfarin is participating in phase III clinical trials for the treatment of thromboembolism and thrombosis. On March 11, 2019, Espero BioPharma Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for tecarfarin for the prevention of systemic thromboembolism of cardiac origin. Tecarfarin is metabolized by esterases, escaping metabolism by the cytochrome P450 system and thereby avoiding cytochrome P450-mediated drug-drug or drug-food interactions as well as genetic variations found in the cytochrome P450 system.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vitamin k epoxide reductase complex subunit 1 isoform 1 22 Target ID: CHEMBL1930 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19845677 \| https://www.ncbi.nlm.nih.gov/pubmed/29202207	Antagonist 2778		0.67 µM [IC50]

PubMed

Title	Date	PubMed
Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.	2009 Nov	19845677
The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation.	2009 Sep 22	19738136
Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.	2011 Apr	20622200

Patents

Sample Use Guides

In Vivo Use Guide

Tecarfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:25:45 GMT 2023` Edited by `admin` on `Fri Dec 15 15:25:45 GMT 2023`
Record UNII	WN1479YT50
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TECARFARIN

Official Name

English

2,2,2-TRIFLUORO-1-METHYL-1-(TRIFLUOROMETHYL)ETHYL 4-((4-HYDROXY-2-OXO-2H-CHROMEN-3-YL)METHYL)BENZOATE

Systematic Name

English

tecarfarin [INN]

Common Name

English

ATI-5923

Code

English

BENZOIC ACID, 4-((4-HYDROXY-2-OXO-2H-1-BENZOPYRAN-3-YL)METHYL)-, 2,2,2-TRIFLUORO-1-METHYL-1-(TRIFLUOROMETHYL)ETHYL ESTER

Common Name

English

Tecarfarin [WHO-DD]

Common Name

English

TECARFARIN [USAN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

659818